Skip to main content
. 2018 Aug 13;128(9):3926–3940. doi: 10.1172/JCI96519

Figure 2. CD8+ T cells are required for maximal efficacy of AZD6738 plus radiation in CT26 tumors.

Figure 2

(A–D) Response of CT26 over time to treatment with AZD6738, IR, or the combination of AZD6738 plus IR in CD8-depleted BALB/c (A and B) and athymic nude (C and D) mice. Dose and time of administration of AZD6738 were the same as in Figure 1. (A and B) Response in CD-depleted BALB/c mice, with 250 μg anti-CD8 antibody (αCD8) administered on days 1–2. Data represent individual tumor volumes (A) or mean tumor volumes ± SEM (B) from 2 independent experiments. n per arm (mice) = 9 vehicle, 8 AZD6738, 8 IR, 10 AZD6738 + IR. ***P < 0.001, ANOVA with Holm-Šidák multiple-comparisons test comparing change in tumor volume from day 1 to day 15 for AZD6738 + IR vs. AZD6738 and AZD6738 + IR vs. IR. Statistical significance not shown for other comparisons/time points. (C and D) Response in athymic nude mice. Data represent individual tumor volumes (C) or mean tumor volumes ± SEM (D) from 1 experiment. n per arm (mice) = 7 vehicle, 7 AZD6738, 8 IR, 8 AZD6738 + IR. Unpaired, 2-tailed t test comparing change in tumor volume from day 1 to day 14 for AZD6738 + IR vs. IR. Statistical significance not shown for other time points.